HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Inan, U. U. Articles by Temel, S. G. Search for Related Content PubMed PubMed Citation Articles by Inan, U. U. Articles by Temel, S. G.

Preclinical Safety Evaluation of Intravitreal Injection of Full-Length Humanized Vascular Endothelial Growth Factor Antibody in Rabbit Eyes

Ümit Übeyt nan,¹ Berrin Avci,² Tuncay Kusbeci,¹ Berkant Kaderli,³ Remzi Avci,³ and Sehime G. Temel⁴

¹From the Department of Ophthalmology, Kocatepe University School of Medicine, Afyon, Turkey; and the Departments of ²Histology and Embryology, ³Ophthalmology, and ⁴Medical Genetics, Uludag University School of Medicine, Bursa, Turkey.

PURPOSE. To evaluate the preclinical safety of intravitreal bevacizumab, which is a full-length humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), in rabbit eyes over a short-term period.

METHODS. Twenty-four rabbits were divided into two groups, each with two subgroups. The first group (groups 1 and 2) received 1.25 mg (0.05 mL) intravitreal bevacizumab, and the second group (groups 3 and 4) received 3.00 mg (0.12 mL) intravitreal bevacizumab. The right eyes were designated as the study eyes, and the left eyes served as a control and received the same volume of saline intravitreally. Groups 1 and 3 were labeled as early groups and scheduled to be terminated at 14 days. Groups 2 and 4, labeled as late groups, were scheduled to be terminated at 28 days. Besides electroretinography (ERG) and visually evoked potentials (VEP), central corneal thickness, intraocular pressure, fundus photography, and anterior segment imaging were performed at baseline and scheduled time points. Enucleated eyes were preserved for light and electron microscopic investigation.

RESULTS. No anterior segment inflammation was observed, except in one eye in group 1 which showed a uveitic reaction. No evidence of retinal toxicity was seen with intravitreal bevacizumab at doses of 1.25 and 3.00 mg, by either ERG or light microscopy. Electron microscopic assessment revealed mitochondrial damage in the inner segments of photoreceptors. Immunohistochemical staining with bax and caspase-3 and -9 showed intensive apoptotic protein expression in all study sections and minimal expression in the control eyes.

CONCLUSIONS. Although electrophysiologic investigation and light microscopy showed normal retinal function and structure, mitochondrial disruption in the inner segments of photoreceptors was detected by electron microscopy, and apoptotic expression was detected after the injection of intravitreal bevacizumab.

This article has been cited by other articles:

				C. Q. Yu, M. Zhang, K. I. Matis, C. Kim, and M. I. Rosenblatt Vascular Endothelial Growth Factor Mediates Corneal Nerve Repair Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 3870 - 3878. [Abstract] [Full Text] [PDF]

				R Karanjia, K T Eng, J Gale, S Sharma, and M W t. Hove Electrophysiological effects of intravitreal Avastin (bevacizumab) in the treatment of exudative age-related macular degeneration Br. J. Ophthalmol., September 1, 2008; 92(9): 1248 - 1252. [Abstract] [Full Text] [PDF]

				S. Kaempf, S. Johnen, A. K. Salz, A. Weinberger, P. Walter, and G. Thumann Effects of Bevacizumab (Avastin) on Retinal Cells in Organotypic Culture Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3164 - 3171. [Abstract] [Full Text] [PDF]

				H. Ameri, G. J. Chader, J.-G. Kim, S. R. Sadda, N. A. Rao, and M. S. Humayun The Effects of Intravitreous Bevacizumab on Retinal Neovascular Membrane and Normal Capillaries in Rabbits Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5708 - 5715. [Abstract] [Full Text] [PDF]